{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:02:48Z","timestamp":1794265368159,"version":"4.9.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To discuss the history of cardiovascular outcomes trials of cholesteryl ester transfer protein (CETP) inhibitors and to describe obicetrapib, a next-generation, oral, once-daily, low-dose CETP inhibitor in late-stage development for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Phase 1 and 2 trials have evaluated the safety and lipid\/lipoprotein effects of obicetrapib as monotherapy, in conjunction with statins, on top of high-intensity statins (HIS), and with ezetimibe on top of HIS. In ROSE2, 10\u00a0mg obicetrapib monotherapy and combined with 10\u00a0mg ezetimibe, each on top of HIS, significantly reduced low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B, total LDL particles, small LDL particles, small, dense LDL-C, and lipoprotein (a), and increased HDL-C. Phase 3 pivotal registration trials including a cardiovascular outcomes trial are underway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Obicetrapib has an excellent safety and tolerability profile and robustly lowers atherogenic lipoproteins and raises HDL-C. As such, obicetrapib may be a promising agent for the treatment of ASCVD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11883-023-01184-1","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T06:01:57Z","timestamp":1703224917000},"page":"35-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments"],"prefix":"10.1007","volume":"26","author":[{"given":"John J. P.","family":"Kastelein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary R.","family":"Dicklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ditmarsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"1184_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11883-023-01087-1","volume":"25","author":"H Xue","year":"2023","unstructured":"Xue H, Zhang M, Liu J, Wang J, Ren G. Structure-based mechanism and inhibition of cholesteryl ester transfer protein. Curr Atheroscler Rep. 2023;25:155\u201366. https:\/\/doi.org\/10.1007\/s11883-023-01087-1.","journal-title":"Curr Atheroscler Rep"},{"key":"1184_CR2","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/oxfordjournals.jbchem.a135418","volume":"98","author":"T Kurasawa","year":"1985","unstructured":"Kurasawa T, Yokoyama S, Miyake Y, Yamamura T, Yamamoto A. Rate of cholesteryl ester transfer between high and low density lipoproteins in human serum and a case with decreased transfer rate in association with hyperalphalipoproteinemia. J Biochem. 1985;98:1499\u2013508. https:\/\/doi.org\/10.1093\/oxfordjournals.jbchem.a135418.","journal-title":"J Biochem"},{"key":"1184_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0021-9150(85)90064-4","volume":"58","author":"J Koizumi","year":"1985","unstructured":"Koizumi J, Mabuchi H, Yoshimura A, Michishita I, Takeda M, Itoh H, et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis. 1985;58:175\u201386. https:\/\/doi.org\/10.1016\/0021-9150(85)90064-4.","journal-title":"Atherosclerosis"},{"key":"1184_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","volume":"323","author":"A Inazu","year":"1990","unstructured":"Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234\u20138. https:\/\/doi.org\/10.1056\/NEJM199011013231803.","journal-title":"N Engl J Med"},{"key":"1184_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5551\/jat.11.110","volume":"11","author":"M Nagano","year":"2004","unstructured":"Nagano M, Yamashita S, Hirano K, Takano M, Maruyama T, Ishihara M, et al. Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb. 2004;11:110\u201321. https:\/\/doi.org\/10.5551\/jat.11.110.","journal-title":"J Atheroscler Thromb"},{"key":"1184_CR6","doi-asserted-by":"publisher","first-page":"9B","DOI":"10.1016\/0002-9149(83)90649-5","volume":"52","author":"WB Kannel","year":"1983","unstructured":"Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol. 1983;52:9B-12B. https:\/\/doi.org\/10.1016\/0002-9149(83)90649-5.","journal-title":"Am J Cardiol"},{"key":"1184_CR7","unstructured":"Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol. 1988;4 Suppl A:5A-10A. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3179802. Accessed\u00a013 Aug 2023."},{"key":"1184_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.cir.79.1.8","volume":"79","author":"DJ Gordon","year":"1989","unstructured":"Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8\u201315. https:\/\/doi.org\/10.1161\/01.cir.79.1.8.","journal-title":"Circulation"},{"issue":"Suppl","key":"1184_CR9","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/0021-9150(96)05852-2","volume":"124","author":"G Assmann","year":"1996","unstructured":"Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(Suppl):S11-20. https:\/\/doi.org\/10.1016\/0021-9150(96)05852-2.","journal-title":"Atherosclerosis."},{"key":"1184_CR10","doi-asserted-by":"publisher","unstructured":"Emerging Risk Factors C, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993\u20132000. https:\/\/doi.org\/10.1001\/jama.2009.1619.","DOI":"10.1001\/jama.2009.1619"},{"key":"1184_CR11","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCRESAHA.119.312617","volume":"124","author":"M Ouimet","year":"2019","unstructured":"Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport. Circ Res. 2019;124:1505\u201318. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.312617.","journal-title":"Circ Res"},{"issue":"1","key":"1184_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/biom13010105","volume":"13","author":"Y Endo","year":"2023","unstructured":"Endo Y, Fujita M, Ikewaki K. HDL functions-current status and future perspectives. Biomolecules. 2023;13(1):105. https:\/\/doi.org\/10.3390\/biom13010105.","journal-title":"Biomolecules."},{"key":"1184_CR13","doi-asserted-by":"publisher","unstructured":"Aim-High Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1107579.","DOI":"10.1056\/NEJMoa1107579"},{"key":"1184_CR14","doi-asserted-by":"publisher","unstructured":"Hps Thrive Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203\u201312. https:\/\/doi.org\/10.1056\/NEJMoa1300955.","DOI":"10.1056\/NEJMoa1300955"},{"key":"1184_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2224","volume":"2","author":"E D\u2019Andrea","year":"2019","unstructured":"D\u2019Andrea E, Hey SP, Ramirez CL, Kesselheim AS. Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2: e192224. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2224.","journal-title":"JAMA Netw Open"},{"key":"1184_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/2047487318816495","volume":"26","author":"H Riaz","year":"2019","unstructured":"Riaz H, Khan SU, Rahman H, Shah NP, Kaluski E, Lincoff AM, et al. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2019;26:533\u201343. https:\/\/doi.org\/10.1177\/2047487318816495.","journal-title":"Eur J Prev Cardiol"},{"key":"1184_CR17","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(10)60656-3.","journal-title":"Lancet"},{"key":"1184_CR18","doi-asserted-by":"publisher","unstructured":"Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev. 2015;2015:CD009580. https:\/\/doi.org\/10.1002\/14651858.CD009580.pub2.","DOI":"10.1002\/14651858.CD009580.pub2"},{"key":"1184_CR19","doi-asserted-by":"publisher","unstructured":"Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-Gonzalez I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016;11:CD009753. https:\/\/doi.org\/10.1002\/14651858.CD009753.pub2.","DOI":"10.1002\/14651858.CD009753.pub2"},{"key":"1184_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4093\/dmj.2020.0001","volume":"44","author":"NH Kim","year":"2020","unstructured":"Kim NH, Kim SG. Fibrates revisited: potential role in cardiovascular risk reduction. Diabetes Metab J. 2020;44:213\u201321. https:\/\/doi.org\/10.4093\/dmj.2020.0001.","journal-title":"Diabetes Metab J"},{"key":"1184_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2021.159063","volume":"1867","author":"EW Kjeldsen","year":"2022","unstructured":"Kjeldsen EW, Thomassen JQ, Frikke-Schmidt R. HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - insights from randomized clinical trials and human genetics. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867: 159063. https:\/\/doi.org\/10.1016\/j.bbalip.2021.159063.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"1184_CR22","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109\u201322. https:\/\/doi.org\/10.1056\/NEJMoa0706628.","journal-title":"N Engl J Med"},{"key":"1184_CR23","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1206797.","journal-title":"N Engl J Med"},{"key":"1184_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4137\/CMC.S32667","volume":"10","author":"CE Kosmas","year":"2016","unstructured":"Kosmas CE, DeJesus E, Rosario D, Vittorio TJ. CETP inhibition: past failures and future hopes. Clin Med Insights Cardiol. 2016;10:37\u201342. https:\/\/doi.org\/10.4137\/CMC.S32667.","journal-title":"Clin Med Insights Cardiol"},{"key":"1184_CR25","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1609581.","journal-title":"N Engl J Med"},{"key":"1184_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","volume":"122","author":"AR Tall","year":"2018","unstructured":"Tall AR, Rader DJ. Trials and tribulations of CETP inhibitors. Circ Res. 2018;122:106\u201312. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311978.","journal-title":"Circ Res"},{"key":"1184_CR27","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1038\/s41467-021-25703-3","volume":"12","author":"AF Schmidt","year":"2021","unstructured":"Schmidt AF, Hunt NB, Gordillo-Maranon M, Charoen P, Drenos F, Kivimaki M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat Commun. 2021;12:5640. https:\/\/doi.org\/10.1038\/s41467-021-25703-3.","journal-title":"Nat Commun"},{"key":"1184_CR28","doi-asserted-by":"publisher","unstructured":"Hps Timi Reveal Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1706444.","DOI":"10.1056\/NEJMoa1706444"},{"key":"1184_CR29","doi-asserted-by":"publisher","unstructured":"\u2022 Nelson AJ, Sniderman AD, Ditmarsch M, Dicklin MR, Nicholls SJ, Davidson MH, et al. Cholesteryl ester transfer protein inhibition reduces major adverse cardiovascular events by lowering apolipoprotein B levels. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms23169417. Review paper describing the evidence for a reduction in cardiovascular disease risk directly proportional to reductions in LDL cholesterol and Apo B levels with CETP inhibitor treatments.","DOI":"10.3390\/ijms23169417"},{"key":"1184_CR30","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","volume":"118","author":"NS Nurmohamed","year":"2022","unstructured":"Nurmohamed NS, Ditmarsch M, Kastelein JJP. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res. 2022;118:2919\u201331. https:\/\/doi.org\/10.1093\/cvr\/cvab350.","journal-title":"Cardiovasc Res"},{"key":"1184_CR31","unstructured":"Merck News Release. Merck provides update on anacetrapib development program. In: Merck & Co, Inc. https:\/\/www.merck.com\/news\/merck-provides-update-on-anacetrapib-development-program\/. Accessed 13 Aug 2023."},{"key":"1184_CR32","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/cpt.700","volume":"102","author":"R Krishna","year":"2017","unstructured":"Krishna R, Gheyas F, Liu Y, Hagen DR, Walker B, Chawla A, et al. Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination. Clin Pharmacol Ther. 2017;102:832\u201340. https:\/\/doi.org\/10.1002\/cpt.700.","journal-title":"Clin Pharmacol Ther"},{"key":"1184_CR33","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/j.atherosclerosis.2020.10.813","volume":"315","author":"JM Lee","year":"2020","unstructured":"Lee JM, Lee YJ, Kwon NY, Ryu KH. Old target, but new drug: 2nd generation CETP inhibitor, CKD-508. Atherosclerosis. 2020;315:e108\u2013281.","journal-title":"Atherosclerosis"},{"key":"1184_CR34","doi-asserted-by":"publisher","first-page":"13215","DOI":"10.1021\/acs.jmedchem.1c00959","volume":"64","author":"P Vachal","year":"2021","unstructured":"Vachal P, Duffy JL, Campeau LC, Amin RP, Mitra K, Murphy BA, et al. Invention of MK-8262, a cholesteryl ester transfer protein (CETP) inhibitor backup to anacetrapib with best-in-class properties. J Med Chem. 2021;64:13215\u201358. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00959.","journal-title":"J Med Chem"},{"key":"1184_CR35","doi-asserted-by":"publisher","unstructured":"\u2022 Ballantyne CM, Ditmarsch M, Kastelein JJ, Nelson AJ, Kling D, Hsieh A, et al. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial. J Clin Lipidol. 2023. https:\/\/doi.org\/10.1016\/j.jacl.2023.05.098. Phase 2b randomized controlled trial showing obicetrapib plus ezetimibe on top of high-intensity statin therapy significantly reduced LDL-C, Apo B, and LDL particles.","DOI":"10.1016\/j.jacl.2023.05.098"},{"key":"1184_CR36","unstructured":"NewAmsterdam Pharma. Evaluate the effect of obicetrapib in patients with HeFH on top of maximum tolerated lipid-modifying therapies (BROOKLYN). In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05425745. Accessed 13 Aug 2023."},{"key":"1184_CR37","unstructured":"NewAmsterdam Pharma. Randomized study to evaluate the effect of obicetrapib on top of maximum tolerated lipid-modifying therapies (BROADWAY). In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05142722. Accessed 13 Aug 2023."},{"key":"1184_CR38","unstructured":"NewAmsterdam Pharma. Cardiovascular outcome study to evaluate the effect of obicetrapib in patients with cardiovascular disease (PREVAIL). In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05202509. Accessed 13 Aug 2023."},{"key":"1184_CR39","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/bcp.12380","volume":"78","author":"J Ford","year":"2014","unstructured":"Ford J, Lawson M, Fowler D, Maruyama N, Mito S, Tomiyasu K, et al. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2014;78:498\u2013508. https:\/\/doi.org\/10.1111\/bcp.12380.","journal-title":"Br J Clin Pharmacol"},{"key":"1184_CR40","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","volume":"386","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386:452\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(15)60158-1.","journal-title":"Lancet"},{"issue":"1137\u201344","key":"1184_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.06.006","volume":"10","author":"JC van Capelleveen","year":"2016","unstructured":"van Capelleveen JC, Kastelein JJ, Zwinderman AH, van Deventer SJ, Collins HL, Adelman SJ, et al. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. J Clin Lipidol. 2016;10(1137\u201344): e3. https:\/\/doi.org\/10.1016\/j.jacl.2016.06.006.","journal-title":"J Clin Lipidol"},{"key":"1184_CR42","doi-asserted-by":"publisher","unstructured":"\u2022 Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28:1672\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01936-7. Phase 2 trial demonstrating significant reductions in LDL-C, non-HDL-C, and ApoB with obicetrapib on a background of high-intensity statin therapy.","DOI":"10.1038\/s41591-022-01936-7"},{"key":"1184_CR43","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2165\/11599310-000000000-00000","volume":"72","author":"DG Johns","year":"2012","unstructured":"Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs. 2012;72:491\u2013507. https:\/\/doi.org\/10.2165\/11599310-000000000-00000.","journal-title":"Drugs"},{"key":"1184_CR44","doi-asserted-by":"publisher","unstructured":"Hps Timi Reveal Collaborative Group Writing Committee, Sammons E, Hopewell JC, Chen F, Stevens W, Wallendszus K, et al. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J. 2022;43:1416\u201324. https:\/\/doi.org\/10.1093\/eurheartj\/ehab863.","DOI":"10.1093\/eurheartj\/ehab863"},{"key":"1184_CR45","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"key":"1184_CR46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.amjcard.2013.08.041","volume":"113","author":"AM Gotto Jr","year":"2014","unstructured":"Gotto AM Jr, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014;113:76\u201383. https:\/\/doi.org\/10.1016\/j.amjcard.2013.08.041.","journal-title":"Am J Cardiol"},{"key":"1184_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.543","volume":"7","author":"DG Johns","year":"2019","unstructured":"Johns DG, Wang SP, Rosa R, Hubert J, Xu S, Chen Y, et al. Impact of drug distribution into adipose on tissue function: the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case. Pharmacol Res Perspect. 2019;7: e00543. https:\/\/doi.org\/10.1002\/prp2.543.","journal-title":"Pharmacol Res Perspect"},{"key":"1184_CR48","doi-asserted-by":"publisher","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"1184_CR49","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","volume":"318","author":"BA Ference","year":"2017","unstructured":"Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA. 2017;318:947\u201356. https:\/\/doi.org\/10.1001\/jama.2017.11467.","journal-title":"JAMA"},{"key":"1184_CR50","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrcardio.2017.156","volume":"14","author":"MV Holmes","year":"2017","unstructured":"Holmes MV, Smith GD. Dyslipidaemia: revealing the effect of CETP inhibition in cardiovascular disease. Nat Rev Cardiol. 2017;14:635\u20136. https:\/\/doi.org\/10.1038\/nrcardio.2017.156.","journal-title":"Nat Rev Cardiol"},{"key":"1184_CR51","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/clpt.2008.109","volume":"84","author":"R Krishna","year":"2008","unstructured":"Krishna R, Bergman AJ, Jin B, Fallon M, Cote J, Van Hoydonck P, et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther. 2008;84:679\u201383. https:\/\/doi.org\/10.1038\/clpt.2008.109.","journal-title":"Clin Pharmacol Ther"},{"key":"1184_CR52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2125.2009.03465.x","volume":"68","author":"R Krishna","year":"2009","unstructured":"Krishna R, Garg A, Panebianco D, Cote J, Bergman AJ, Van Hoydonck P, et al. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009;68:535\u201345. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03465.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1184_CR53","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/jphp.12287","volume":"66","author":"JG Suico","year":"2014","unstructured":"Suico JG, Wang MD, Friedrich S, Cannady EA, Konkoy CS, Ruotolo G, et al. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults. J Pharm Pharmacol. 2014;66:1576\u201385. https:\/\/doi.org\/10.1111\/jphp.12287.","journal-title":"J Pharm Pharmacol"},{"key":"1184_CR54","doi-asserted-by":"publisher","first-page":"37321","DOI":"10.1074\/jbc.M112.380063","volume":"287","author":"S Liu","year":"2012","unstructured":"Liu S, Mistry A, Reynolds JM, Lloyd DB, Griffor MC, Perry DA, et al. Crystal structures of cholesteryl ester transfer protein in complex with inhibitors. J Biol Chem. 2012;287:37321\u20139. https:\/\/doi.org\/10.1074\/jbc.M112.380063.","journal-title":"J Biol Chem"},{"key":"1184_CR55","unstructured":"NewAmsterdam Pharma. Bioequivalence study of capsule and tablet formulations of TA-8995. In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02523391. Accessed 13 Aug 2023."},{"key":"1184_CR56","unstructured":"NewAmsterdam Pharma. Study of the electrocardiographic effects of TA-8995. In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02241759. Accessed 13 Aug 2023."},{"key":"1184_CR57","unstructured":"NewAmsterdam Pharma. A preliminary drug drug interaction study with TA-8995. In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02124954. Accessed 13 Aug 2023."},{"key":"1184_CR58","unstructured":"NewAmsterdam Pharma. ADME study in healthy male subjects with TA-8995. In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02408055. Accessed 13 Aug 2023."},{"key":"1184_CR59","unstructured":"NewAmsterdam Pharma. A study of the effects of TA-8995 on Lp(a) in subjects with elevated Lp(a). In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02241772. Accessed 13 Aug 2023."},{"key":"1184_CR60","unstructured":"NewAmsterdam Pharma. A dose-finding study in Japanese patients to evaluate the effect of obicetrapib as an adjunct to stable statin therapy. In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05421078. Accessed 13 Aug 2023."},{"key":"1184_CR61","unstructured":"NewAmsterdam Pharma. Randomized study of obicetrapib in combination with ezetimibe (OCEAN). In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04770389. Accessed 13 Aug 2023."},{"key":"1184_CR62","unstructured":"NewAmsterdam Pharma Press Release: NewAmsterdam Pharma announces positive topline results from phase 2b dose-finding trial evaluating obicetrapib in Japanese patients. In.; 2023."},{"key":"1184_CR63","unstructured":"NewAmsterdam Pharma. Proof-of-concept, open-label study in patients with early Alzheimer\u2019s disease. In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05161715. Accessed 13 Aug 2023."},{"key":"1184_CR64","unstructured":"NewAmsterdam Pharma. Investigating the effect of obicetrapib on lipoprotein metabolism. In: U.S. Department of Health and Human Services, National Institutes of Health, National LIbrary of Medicine, National Center for Biotechnology Information, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05972278. Accessed 13 Aug 2023."},{"key":"1184_CR65","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279\u201389. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047.","journal-title":"Eur J Prev Cardiol"},{"key":"1184_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6:1\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2021.1810.","journal-title":"JAMA Cardiol"},{"key":"1184_CR67","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0735-1097(23)01675-3","volume":"81","author":"K Wilemon","year":"2023","unstructured":"Wilemon K, MacDougall D, McGowan M, Howard W, Myers K. 71% of high risk hypercholesterolemia patients never reach ACC AHA guidelines. J Am Coll Cardiol. 2023;81:1231.","journal-title":"J Am Coll Cardiol"},{"key":"1184_CR68","doi-asserted-by":"publisher","unstructured":"Casula M, Colpani O, Xie S, Catapano AL, Baragetti A. HDL in atherosclerotic cardiovascular disease: In Search of a Role. Cells. 2021;10. https:\/\/doi.org\/10.3390\/cells10081869.","DOI":"10.3390\/cells10081869"},{"key":"1184_CR69","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.2174\/0929867328666210208182326","volume":"28","author":"S Ganjali","year":"2021","unstructured":"Ganjali S, Watts GF, Banach M, Reiner Z, Nachtigal P, Sahebkar A. The yin and yang of high-density lipoprotein and atherosclerotic cardiovascular disease: focusing on functionality and cholesterol efflux to reframe the HDL hypothesis. Curr Med Chem. 2021;28:6066\u201381. https:\/\/doi.org\/10.2174\/0929867328666210208182326.","journal-title":"Curr Med Chem"},{"key":"1184_CR70","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamacardio.2021.3728","volume":"7","author":"LT Nordestgaard","year":"2022","unstructured":"Nordestgaard LT, Christoffersen M, Lauridsen BK, Afzal S, Nordestgaard BG, Frikke-Schmidt R, et al. Long-term benefits and harms associated with genetic cholesteryl ester transfer protein deficiency in the general population. JAMA Cardiol. 2022;7:55\u201364. https:\/\/doi.org\/10.1001\/jamacardio.2021.3728.","journal-title":"JAMA Cardiol"},{"key":"1184_CR71","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","volume":"48","author":"LG Fritsche","year":"2016","unstructured":"Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48:134\u201343. https:\/\/doi.org\/10.1038\/ng.3448.","journal-title":"Nat Genet"},{"key":"1184_CR72","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1001\/jamacardio.2022.1276","volume":"7","author":"AR Tall","year":"2022","unstructured":"Tall AR, Rader DJ, Kastelein JJP. Macular degeneration and CETP inhibition. JAMA Cardiol. 2022;7:774\u20135. https:\/\/doi.org\/10.1001\/jamacardio.2022.1276.","journal-title":"JAMA Cardiol"},{"key":"1184_CR73","doi-asserted-by":"publisher","first-page":"13601","DOI":"10.1074\/jbc.RA119.012305","volume":"295","author":"UL Kelly","year":"2020","unstructured":"Kelly UL, Grigsby D, Cady MA, Landowski M, Skiba NP, Liu J, et al. High-density lipoproteins are a potential therapeutic target for age-related macular degeneration. J Biol Chem. 2020;295:13601\u201316. https:\/\/doi.org\/10.1074\/jbc.RA119.012305.","journal-title":"J Biol Chem"},{"key":"1184_CR74","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/MOL.0000000000000473","volume":"29","author":"LF Reeskamp","year":"2018","unstructured":"Reeskamp LF, Meessen ECE, Groen AK. Transintestinal cholesterol excretion in humans. Curr Opin Lipidol. 2018;29:10\u20137. https:\/\/doi.org\/10.1097\/MOL.0000000000000473.","journal-title":"Curr Opin Lipidol"},{"key":"1184_CR75","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1161\/ATVBAHA.119.312952","volume":"39","author":"J Li","year":"2019","unstructured":"Li J, Pijut SS, Wang Y, Ji A, Kaur R, Temel RE, et al. Simultaneous determination of biliary and intestinal cholesterol secretion reveals that CETP (cholesteryl ester transfer protein) alters elimination route in mice. Arterioscler Thromb Vasc Biol. 2019;39:1986\u201395. https:\/\/doi.org\/10.1161\/ATVBAHA.119.312952.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1184_CR76","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1172\/JCI118196","volume":"96","author":"K Ikewaki","year":"1995","unstructured":"Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Fairwell T, Zech LA, et al. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest. 1995;96:1573\u201381. https:\/\/doi.org\/10.1172\/JCI118196.","journal-title":"J Clin Invest"},{"key":"1184_CR77","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1161\/01.ATV.0000205595.19612.c9","volume":"26","author":"AH Klerkx","year":"2006","unstructured":"Klerkx AH, El Harchaoui K, van der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ, et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol. 2006;26:706\u201315. https:\/\/doi.org\/10.1161\/01.ATV.0000205595.19612.c9.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1184_CR78","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1172\/JCI80025","volume":"125","author":"JS Millar","year":"2015","unstructured":"Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Baer AL, et al. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest. 2015;125:2510\u201322. https:\/\/doi.org\/10.1172\/JCI80025.","journal-title":"J Clin Invest"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01184-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-023-01184-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01184-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T03:23:19Z","timestamp":1706930599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-023-01184-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1184"],"URL":"https:\/\/doi.org\/10.1007\/s11883-023-01184-1","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"5 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.J.P.K, A.H., M.D., and M.H.D. are employees of NewAmsterdam Pharma and they also report that they receive stock or stock options. J.J.P.K is the Chief Scientific Officer of NewAmsterdam Pharma. A.H. is the Executive Director, R&D, NewAmsterdam Pharma. M.D. is the Chief Development Officer of NewAmsterdam Pharma. M.H.D. is the Chief Executive Officer of NewAmsterdam Pharma. M.R.D., as an employee of Midwest Biomedical Research, is a consultant for NewAmsterdam Pharma. In addition, M.R.D., as an employee of Midwest Biomedical Research, reports the following companies contracted consulting and\/or research with their institution and it received the consulting fees and grant funding from Acasti Pharma, Beren Therapeutics, Eli Lilly and Company, Indiana University and Foundation, Matinas BioPharma, NewAmsterdam Pharma, and 89Bio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki Declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}